Burfiralimab

Modify Date: 2024-04-06 14:06:15

Burfiralimab structure	Common Name	Burfiralimab
	CAS Number	2460809-80-5	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Burfiralimab

Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1].

Name	Burfiralimab

Description	Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Signaling Pathways >> Anti-infection >> SARS-CoV Research Areas >> Inflammation/Immunology
References	[1]. Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.

No Any Chemical & Physical Properties

Burfiralimab

Use of Burfiralimab

Names

Burfiralimab Biological Activity

Chemical & Physical Properties